220 related articles for article (PubMed ID: 12908853)
1. Factors affecting the clinical development of cytochrome p450 3A substrates.
Gibbs MA; Hosea NA
Clin Pharmacokinet; 2003; 42(11):969-84. PubMed ID: 12908853
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
3. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
4. Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate.
Kimzey AL; Weitz KK; Guengerich FP; Zangar RC
Biochemistry; 2003 Nov; 42(43):12691-9. PubMed ID: 14580217
[TBL] [Abstract][Full Text] [Related]
5. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
8. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
9. Analysis of medaka cytochrome P450 3A homotropic and heterotropic cooperativity.
Kullman SW; Kashiwada S; Hinton DE
Mar Environ Res; 2004; 58(2-5):469-73. PubMed ID: 15178067
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
11. The influence of age and sex on the clearance of cytochrome P450 3A substrates.
Cotreau MM; von Moltke LL; Greenblatt DJ
Clin Pharmacokinet; 2005; 44(1):33-60. PubMed ID: 15634031
[TBL] [Abstract][Full Text] [Related]
12. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
Preskorn SH; Alderman J; Greenblatt DJ; Horst WD
Psychopharmacol Bull; 1997; 33(4):659-65. PubMed ID: 9493476
[TBL] [Abstract][Full Text] [Related]
13. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
14. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A and their regulation.
Burk O; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):105-24. PubMed ID: 14569421
[TBL] [Abstract][Full Text] [Related]
16. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
17. Properties and regional expression of a CYP3A-like protein in channel catfish intestine.
James MO; Lou Z; Rowland-Faux L; Celander MC
Aquat Toxicol; 2005 May; 72(4):361-71. PubMed ID: 15848255
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
19. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
20. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
